In 2023, Eddie J. Sullivan earned $402.56K in total compensation at SAB Biotherapeutics, primarily from $377.20K salary. Most recently acquired 3,480 shares in Dec 2023. Currently holds stock worth $20.82M. Led SAB Biotherapeutics as CEO for 2 years.
Compensation History
Annual executive compensation data for Eddie J. Sullivan, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$402.56K
Salary
$377.20K
Bonus
$0.00
Other
$25.36K
Salary
$377.20KBoard Justification
The compensation philosophy aligns with company performance and aims to attract and retain top talent.
Bonus
$0.00Board Justification
No non-equity incentive plan compensation was awarded in 2023.
Other Compensation
$25.36KBoard Justification
Includes lease payment for an apartment and employer matching contributions under the 401(k) plan.
Restricted Stock
Board Justification
No stock awards were vested in 2023.
Performance Metrics
Performance metrics are not specified for the year 2023.
Eddie J. Sullivan
Ex-CEO of SAB Biotherapeutics
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
CEO of SAB Biotherapeutics for
2 years 10 months (Mar 2021 - Jan 2024)
Previous Experience
President and Chief Executive Officer of OLD SAB
Other SAB Biotherapeutics CEOs
Holdings
Track Eddie J. Sullivan's stock holdings and portfolio value over time.
Insider Trading
Eddie J. Sullivan's recent stock transactions, purchases, and sales filed with the SEC.
$3.06K
SABS at $0.88/share
Dec 7, 2023
Purchase
$10.32K
SABS at $0.74/share
Sep 7, 2022
Purchase
$26.27M
SABS at $5.04/share
Oct 7, 2021
Received
Rivals
Compare Eddie J. Sullivan with competitor CEOs and industry peers.